Literature DB >> 16877458

Is TNFalpha really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab.

M Dziadzio, V Reddy, S Rahman, C Mummery, A Keat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16877458     DOI： 10.1093/rheumatology/kel232

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

Review 1.  Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature.

Authors:  Melissa Padovan; Luisa Maria Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

Review 2.  Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature.

Authors:  Rikitha Menezes; Alexander Pantelyat; Izlem Izbudak; Julius Birnbaum
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

Review 3.  Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα.

Authors:  Massimo Tortarolo; Daniele Lo Coco; Pietro Veglianese; Antonio Vallarola; Maria Teresa Giordana; Gabriella Marcon; Ettore Beghi; Marco Poloni; Michael J Strong; Anand M Iyer; Eleonora Aronica; Caterina Bendotti
Journal:  Mediators Inflamm       Date:  2017-09-10       Impact factor: 4.711

Review 4.  Motor neuron disease in a patient with overlap syndrome (rheumatoid arthritis; systemic lupus erythematosus, Sjogren's syndrome).

Authors:  Ebru Atalar; Fatma Gül Yurdakul; Kevser Gök; Tuba Güler; Şükran Erten; Evren Yaşar; Hatice Bodur
Journal:  Rheumatol Int       Date:  2022-09-18       Impact factor: 3.580

5.  Is there a link between amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors?

Authors:  A Börjesson; B Grundmark; H Olaisson; L Waldenlind
Journal:  Ups J Med Sci       Date:  2013-04-08       Impact factor: 2.384

6.  LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L.

Authors:  Lucia Taraborrelli; Nieves Peltzer; Antonella Montinaro; Sebastian Kupka; Eva Rieser; Torsten Hartwig; Aida Sarr; Maurice Darding; Peter Draber; Tobias L Haas; Ayse Akarca; Teresa Marafioti; Manolis Pasparakis; John Bertin; Peter J Gough; Philippe Bouillet; Andreas Strasser; Martin Leverkus; John Silke; Henning Walczak
Journal:  Nat Commun       Date:  2018-09-25       Impact factor: 14.919
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.